Subscribe

What are you looking for?

Main Menu

明報新聞網

兆科眼科：治療兒童近視加深新藥上市申請獲國家藥監局受理

Future Wealths
Future Wealths
9 7 月, 2025
One Min Read
11 Views
0 Comments
兆科眼科（6622） 自願公告，中國國家藥品監督管理局最近受理公司核心產品之一、用於治療兒童近視加深的NVK002（硫酸阿托品滴眼液0.02%） 的新藥上市申請，該新藥申請分類為II類創新藥。董事會相信，NVK002的潛在商業化將讓公司藉滿足中國龐大的需求缺口，建立領導地位。

原文: https://finance.mingpao.com/fin/instantf/20250709/1752057939317/%e5%85%86%e7%a7%91%e7%9c%bc%e7%a7%91-%e6%b2%bb%e7%99%82%e5%85%92%e7%ab%a5%e8%bf%91%e8%a6%96%e5%8a%a0%e6%b7%b1%e6%96%b0%e8%97%a5%e4%b8%8a%e5%b8%82%e7%94%b3%e8%ab%8b%e7%8d%b2%e5%9c%8b%e5%ae%b6%e8%97%a5%e7%9b%a3%e5%b1%80%e5%8f%97%e7%90%86

Last Update: 9 7 月, 2025

Please share this article if you like it!

Link Copied!
Future Wealths
Written By

Future Wealths

Other Articles

Related Posts

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept